Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.13 USD | +0.73% | +0.93% | +0.27% |
Financials (USD)
Sales 2024 * | 143M | Sales 2025 * | 33.68M | Capitalization | 477M |
---|---|---|---|---|---|
Net income 2024 * | -20M | Net income 2025 * | -147M | EV / Sales 2024 * | 2.62 x |
Net cash position 2024 * | 104M | Net cash position 2025 * | 141M | EV / Sales 2025 * | 9.97 x |
P/E ratio 2024 * |
-30.4
x | P/E ratio 2025 * |
-3.97
x | Employees | 160 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.37% |
Latest transcript on Entrada Therapeutics, Inc.
1 day | +0.73% | ||
1 week | +1.20% | ||
Current month | +27.68% | ||
1 month | +17.38% | ||
3 months | +13.33% | ||
6 months | +33.19% | ||
Current year | +0.27% |
Managers | Title | Age | Since |
---|---|---|---|
Dipal Doshi
CEO | Chief Executive Officer | 48 | 17-07-31 |
Kory Wentworth
DFI | Director of Finance/CFO | 45 | 20-10-31 |
Nathan Dowden
PSD | President | 54 | 19-11-03 |
Members of the board | Title | Age | Since |
---|---|---|---|
Peter Kim
BRD | Director/Board Member | 65 | 20-11-30 |
Mary Thistle
BRD | Director/Board Member | 64 | 21-05-03 |
Gina Chapman
BRD | Director/Board Member | 57 | 23-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +4.20% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 15.13 | +0.73% | 33,861 |
24-05-23 | 15.02 | -6.18% | 65,350 |
24-05-22 | 16.01 | +1.97% | 59,963 |
24-05-21 | 15.7 | +2.48% | 71,074 |
24-05-20 | 15.32 | +2.20% | 100,905 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.27% | 477M | |
+12.30% | 116B | |
+12.15% | 106B | |
-8.14% | 23.89B | |
-1.69% | 21.58B | |
-10.60% | 18.96B | |
-41.25% | 16.96B | |
-15.33% | 16.33B | |
+5.80% | 14.14B | |
+28.03% | 12.02B |
- Stock Market
- Equities
- TRDA Stock